Navigation Links
Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
Date:10/24/2007

qually in Phase 3/4 development costs, and will share equally in sales and marketing expenses and profits of any product commercialized.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa- 2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancers.

For more information about HGS, please visit the Company's Web site at http://www.hgsi.com. To view the AACR-NCI-EORTC poster presentation reporting results of the Phase 1b clinical trial of HGS-ETR2 in combination with chemotherapy, click here. To view the poster presentation reporting results of the preclinical studies of HGS-ETR1 and HGS-ETR2 with chemotherapy in cholangiocarcinoma, click here. Health professionals or patients interested in HGS-ETR1 or HGS-ETR2 clinical trials or other studies involving HGS products may inquire via the Contact Us section of the Company's web site, http://www.hgsi.com/products/request.html, or by calling us at (301) 610-5790, extension 3550.

Safe Harbor Statement

This announcement contains forward-looking stateme
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Apollos human proteins boost stem cell research
5. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the ... Industrial Average finished the day 0.42% lower at 16,915.07, and ... were broad based as eight out of ten sectors ended ... Index ended the day at 711.88, down 0.02%, while the ... has initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... , , , Funding and ... NEW YORK, Dec. 14 The Microbicides Development Programme announced ... conducted among almost 9,400 women in four African countries, found ... of HIV infection. , Reacting to today,s announcement, AVAC executive ...
... InterMune, Inc. (Nasdaq: ITMN ) today announced that Steve ... the 2009 DB-Biotech Boston Confab on December 15, 2009 at ... audio webcast of the presentation, investors and other interested parties ... corporate website at www.intermune.com. The company recommends logging on ...
Cached Medicine Technology:AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 2AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial 3
(Date:7/13/2014)... is a professional supplier of funeral products. According to the ... in the global market. Recently, the company has announced its ... special offer for all the newly released items. , ... are made with superb materials. As is commonly noted, a ... to the departed saint. MillionaireCasket.com is always here to help. ...
(Date:7/13/2014)... to get the best treatment and variations in the ... survival for blood cancer patients still varies widely between ... of survival in European adults to date, published in ... is that 5-year survival for most cancers of the ... likely reflecting the approval of new targeted drugs in ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway in ... up potential new therapeutic strategies for an enigmatic ... a chronic inflammatory disorder of the esophagus. The ... foods and an over-accumulation in the esophagus of ... body,s immune system). EoE can cause a variety ...
(Date:7/13/2014)... 2014 Chromatography system is a ... various types of biological samples such as air ... mixture into two phase, namely mobile phase and ... run over the stationary phase, followed by the ... provide the separation of mixture. Chromatography system plays ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3
... fibronectin can predict whether a pregnant woman is at ... risk for pre-term births are women with previous pre-term ... suffer from diabetes and/or hypertension. The current approach for ... is the use of a clinical scoring system, ...
... technology born of genetic ,engineering, and known as naked ... such as multiple ,sclerosis and rheumatoid arthritis. , ... In multiple sclerosis (MS) and ,rheumatoid arthritis (RA), the ... myelin sheath of nerves falls ,victim, while in RA, ...
... requiring heart bypass ,speeds recovery in children undergoing ... clinical trial published in The Lancet., , ... underwent long and difficult surgeries. Following trauma or ... concentrations plummet. Many experts thought this was an ...
... derivatives from garlic may potentially play a role in ... review published in a recent issue of Nutrition in ... effect of garlic on risk factors for heart disease. ... LDL ("bad") ,cholesterol and blood pressure. It may also ...
... painkillers to ease the agony of terminally ill patients ... the practice, comparing it to euthanasia, but doctors at ... doses of drugs such as morphine live just as ... research published in The Lancet medical journal, they compared ...
... Antibiotcs seem to treat or prevent the symptoms of autism ... is affected by autism. Currently there are no treatments for ... found that a subset of patients with autism who experience ... by antibiotic vancomycin. ,Interestingly the study was done ...
Cached Medicine News:
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Medicine Products: